We advised Medtide on its IPO and HKEX listing

Davis Polk advised Medtide Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and its international offering pursuant to Regulation S. The gross proceeds of the offering were approximately HK$411.2 million.

Medtide Inc. is peptide-focused contract research, development and manufacturing organization (CRDMO) that offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production.

The Davis Polk corporate team included partners Xuelin (Steve) Wang and Jason Xu, counsel – registered foreign lawyer Jennifer (Yujia) Jiang, counsel Wendy Kan, associates Edwin Lee and registered foreign lawyer Eva Xu. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.

Copy link to share post